Dysphagia Therapy
Non-surgical, neurostimulation therapy
Dysphagia Therapy
Like No Other
Non-surgical, neurostimulation therapy
to restore swallowing control and reduce length of stay.
Dysphagia Therapy
Like No Other
Non-surgical, neurostimulation therapy
to restore swallowing control and reduce length of stay.
Targeting and restoring the neurological components of swallowing coordination and control that are disrupted due to brain injury or prolonged mechanical ventilation.
Robust Evidence
Randomized control trials demonstrate clinically significant improvements using a range of dysphagia outcome measures.
Favorable Economics
Treatment can be delivered earlier than other dysphagia interventions and has been shown to support faster recovery and reduced length of stay.
Seamless Integration
Simple to integrate into existing multidisciplinary care. Treatment sessions are targeted, quick and require limited patient input to optimize and deliver.
Robust Evidence
Randomized control trials demonstrate clinically significant improvements using a range of dysphagia outcome measures.
Favorable Economics
Treatment can be delivered earlier than other dysphagia interventions and has been shown to support faster recovery and reduced length of stay.
Seamless Integration
Simple to integrate into existing multidisciplinary care. Treatment sessions are targeted, quick and require limited patient input to optimize and deliver.
Dysphagia is Common, Costly,
and Harmful to Patients
Dysphagia is Common, Costly, and Harmful to Patients
Swallowing impairment, called dysphagia, affects millions of people worldwide and can have a profound health and economic impact.
Extended
Hospital Stay
Hospital Stay
High Burden
of Care
of Care
Poor Quality
of Life
of Life
Treating the Root Cause of Dysphagia.
Phagenyx® Neurostimulation System
Introducing the first and only treatment using pharyngeal electrical stimulation (PES) to restore swallowing control, facilitate airway protection, and accelerate recovery.
Personalized levels of PES, delivered at the earliest stages after injury, enhance neurorehabilitation and reorganization of swallowing control, while requiring minimal patient participation.
Video Duration: 02:40
Video Duration: 05:50
Simple & Safe
Non-surgical therapy with 10+ years of clinical use in Europe
Adjust the catheter to reflect patient anatomy and then insert. When ready to deliver treatment, connect the catheter to the Base Station.
Follow Base Station on-screen instructions to measure patient sensory capacity and optimize the stimulation level
Deliver optimized stimulation for 10 minutes once per day. On completion, disconnect the Base Station. Leave the catheter in place.
Repeat for 3-6 days as clinically indicated. On completion of the treatment regimen, remove the catheter or leave in place for feeding for up to 30 days
Extensive Clinical Evidence
Demonstrated Safety in Multiple Patient Populations
Years
0
+
Randomized
Control Trials
Control Trials
0
+
Publications
0
+
SEPTEMBER 5, 2024
|
Press Release
Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing
- Accomplished leader brings strong track record of commercial expansion in the US
- Company is focused on accelerating uptake of Phagenyx® to treat more patients in the US and Europe
- Phagenyx® is a first-of-its-kind therapy using neurostimulation to restore swallowing control in patients with severe swallowing difficulties (dysphagia)
MANCHESTER, England, Sept. 5, 2024 /PRNewswire/ — Phagenesis, a pioneering company that has developed a first-of-its-kind neurostimulation system to treat swallowing dysfunction, today announced the appointment of Chad Hoskins as Chief Executive Officer (CEO). The seasoned executive brings decades of experience in scaling innovative MedTech therapies, driving commercial growth in the US and delivering on strategic objectives.
“We are extremely excited to have Chad join the company at this critical phase of growth as we build on our success in Europe and expand the use of Phagenyx® in the US,” said Oern Stuge, MD, Chairman of the Board of Directors, Phagenesis. “His relentless focus on improving patient care and deep experience in commercializing novel technologies will bolster the company’s efforts to bring our life-changing therapy to more patients in the US, Europe, and beyond.”
COMPANY
LEADERSHIP
BOARD OF DIRECTORS
COMPANY
Founded in 2007, Phagenesis is committed to scientific and clinical excellence in the development of novel therapies to treat patients suffering from neurogenic dysphagia.
The foundational science and clinical evidence for the pharyngeal electrical stimulation used in Phagenyx, has been peer reviewed and published at the highest level.
First to map the swallow motor cortex in health & disease.
Read more
First to show that dysphagia recovery is due to functional reorganization of the swallow motor cortex.
Read more
First to show that long-term reorganization of the cortex can be driven by short term sensory stimulation.
Read more
First to show that sensory stimulation driven reorganization, results in functional swallow recovery.
Read more
First in a multicenter RCT to show that Phagenyx® responders had a statistically significant shorter length of stay versus non-responders.
Read more
First to demonstrate in a multicenter registry of real-world data clinically significant improvements in CNS, nonCNS, mechanically ventilated, and non-ventilated patients using a range of dysphagia outcome measures.
Read more
LEADERSHIP
CHAD HOSKINS
Chief Executive Officer
CONOR MULROONEY
Co-Founder & Chief Operating Officer
ANDRE NEL
Chief Financial Officer
SHAHEEN HAMDY
Co-Founder & Chief Scientific Officer
BORIS DEUTSCHMANN
Director European Sales
SCOTT GRANT
VP US Therapy Development
ANIL KENI
VP Global Marketing
STEPHEN HALSTEAD
Head of QA/RA
KATE ECKLUND
VP Clinical Affairs
BOARD OF DIRECTORS
DREW BURDON
Director
Partner EQT Lifesciences
MARK WYATT
Director
Investment Director Northern Gritstone
MICHAEL SJÖSTRÖM
Director
Co-founder / Partner Sectoral Asset Management
CHAD HOSKINS
Director
CEO Phagenesis
Get more information
For more information about Phagenesis or the Phagenyx System, please complete the form below.
Come work with us
We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at careers@phagenesis.com or view our open positions on LinkedIn.
Get more information
For more information about Phagenesis or the Phagenyx System, please complete the form below.
Come work with us
We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at jobs@phagenesis.com or view our open positions on LinkedIn.
Get more information
For more information about Phagenesis or the Phagenyx System, please complete the form below.
Come work with us
We are looking for new talent to fuel our next stage of growth. If you are interested in joining our dynamic team, reach out to us at jobs@phagenesis.com or view our open positions on LinkedIn.
